Q3 2024 Boule Diagnostics AB Earnings Call Transcript
Key Points
- Boule Diagnostics AB (STU:8BD) reported significant improvements in operating profit and margin, with adjusted EBIT improving by 93.7% to reach 15.3 million Swedish crowns.
- The company achieved an adjusted gross margin improvement to 47%, up from 41.4%, due to favorable mix and efficiency gains.
- Boule Diagnostics AB (STU:8BD) recognized 16 million in annual savings potential through extensive reorganization efforts.
- OEM sales showed strong performance, growing 51% in Q3 and 17% year-to-date, indicating a promising growth area.
- The company is on track to ramp up manufacturing in India, which is expected to positively impact margins despite a negative impact on top-line sales.
- Sales were negatively impacted by lower instrument and consumable sales, with a 6.6% decline in Q3 sales.
- The transition to a license manufacturing model in India is expected to negatively impact top-line sales by an estimated 30 million annually.
- Boule Diagnostics AB (STU:8BD) reported two significant one-time costs, including a non-cash cost of 265 million Swedish crowns due to project impairment.
- The company is facing challenges in Asia and South America due to competition from low-cost Chinese manufacturers and a market shift towards five-part technology.
- Cash flow from operating activities was weaker in the quarter, mainly due to higher restructuring costs and tax penalties.
Good morning, everybody and welcome to the third quarter's earning call for bull diagnostics.
I'm Holger Lembrer CFO for both diagnostics. And with me, I have our CEO Torben Nielsen.
After our presentation of the third quarter's earnings, we will open up for questions. Please also feel free to type questions into the chat field with that. I'm leaving over to Torben.
Thank you. Good morning and a warm welcome to everybody who's decided to join this Q3 earnings call. We'll begin by taking a look at the Q3 highlights.
Overall, it was a stable quarter in which we delivered slightly below. Last year.
Sales was negatively impacted by lower instrument and consumable sales.
Consumable sales was as expected impacted by the transition to license manufacturing model in India.
And we should expect to see this impact increase as we ramp up production in India for both consumables and in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
